Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

BACKGROUND: The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy with bevacizumab monotherapy. METHODS: This was a 2-part randomized phase 2 study. E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Field, Kathryn M., Simes, John, Nowak, Anna K., Cher, Lawrence, Wheeler, Helen, Hovey, Elizabeth J., Brown, Christopher S.B., Barnes, Elizabeth H., Sawkins, Kate, Livingstone, Ann, Freilich, Ron, Phal, Pramit M., Fitt, Greg, Rosenthal, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648304/
https://ncbi.nlm.nih.gov/pubmed/26130744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados